ASCO GU 2018 Bladder Cancer

Viewing 1-20 of 45 articles

ASCO GU 2018: Erdafitinib, (FGFR) a Pan-fibroblast Growth Factor Receptor Inhibitor, in Patients with Metastatic or Unresectable Urothelial Carcinoma and FGFR Alterations

ASCO GU 2018: Docetaxel with or without Ramucirumab After Immune Checkpoint Inhibition in Platinum-refractory Metastatic Urothelial Carcinoma (Muc): Prespecified Subgroup Analysis from the Phase 3 Range Trial

ASCO GU 2018: Size-focality-invasion in Upper Tract Urothelial Carcinoma - A Novel Imaging-Based Score To Predict Survival Outcomes

ASCO GU 2018: Effectiveness of Transurethral Resection Plus Systemic Chemotherapy as Definitive Treatment for Muscle-Invasive Bladder Cancer

ASCO GU 2018: Impact of Number of Cycles of Platinum-based First-line Chemotherapy for Advanced Urothelial Carcinoma

ASCO GU 2018: Clinical Outcomes of Patients with Histologic Variants of Urothelial Carcinoma Treated with Tetra-Modality Bladder-Sparing Protocol Incorporating Consolidative Partial Cystectomy

ASCO GU 2018: Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer

ASCO GU 2018: Utilization and Outcomes of Chemoprophylaxis for the Prevention of Venous Thromboembolism Following Radical Cystectomy: A Population-Based Study

ASCO GU 2018: Utility Of Lymph Node Dissection for Clinical Node Negative Upper Tract Urothelial Cell Carcinoma: A Multicenter Study

ASCO GU 2018: Defining the DNA Damage Repair Genomic Landscape of Urothelial Carcinoma of the Bladder

ASCO GU 2018: Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

ASCO GU 2018: A Decision-Support Tool to Assist Muscle-Invasive Bladder Cancer Patients Choosing Between Radical Cystectomy and Chemoradiotherapy

ASCO GU 2018: Is Radical Radiotherapy Effective for Elderly Patients with Muscle Invasive Bladder Cancer?

ASCO GU 2018: Interim Results from PURE-01: A Phase 2, Open-Label Study of Neoadjuvant Pembrolizumab Before Radical Cystectomy for Muscle-Invasive Urothelial Bladder Carcinoma

ASCO GU 2018: A Randomized Phase III Double-Blind Clinical Trial (S1600) Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

ASCO GU 2018: Evaluation of a 29 Gene Classifier for Basal/Non Basal Prediction in Muscle-Invasive Bladder Cancer FFPE Samples

ASCO GU 2018: Role of Immunotherapy in Patients Undergoing Radiation Therapy for Bladder Cancer

ASCO GU 2018: Best of Journals: Urothelial Carcinoma - Medical Oncology

ASCO GU 2018: Nivolumab Plus Ipilimumab Versus Standard of Care with Previously Untreated Unresectable or Metastatic Urothelial Carcinoma

ASCO GU 2018: RNA-sequencing to Identify Three Different Molecular Grades and Immune Checkpoint Cascades with Distinct Clinical Behavior in NMIBC

1
2
3